BioSpace News Archive

Arthur A. Levin, Ph.D, executive vice president of research and development at Avidity Biosciences LLC, a biotechnology company advancing Antibody- Oligonucleotide Conjugates (AOCs) as a new class of precision medicines, today published a review titled, “Treating Disease at the RNA Level with Oligonucleotides” in the January 3, 2018, issue of the New England Journal of Medicine1.

New influencer campaign urges people to schedule their annual check-up and talk with their health care provider about their total health - body and mind

Riley will be on a panel moderated by NBC News Anchor Richard Lui, and with senior executives from Embodied Labs, Dthera Sciences and Ageless Innovation -- Joy for All Companion Pets, to discuss the growing use of technology for the treatment and management of Alzheimer’s Disease.

Bain Capital Double Impact, the impact investing business of Bain Capital, today announced the acquisition of HealthDrive, a specialty provider of on-site dentistry, optometry, podiatry, and audiology to residents in long-term care, skilled nursing, and assisted living facilities.

The Green Organic Dutchman Holdings Ltd. is pleased to announce it has signed a royalty-bearing commercial sublicense (the “Agreement”) with EnWave Corporation and Tilray, Inc.

Mr. Yearick will oversee Endotronix’s worldwide sales and marketing efforts for the Cordella™ Heart Failure System

Peloton Therapeutics, Inc., a clinical-stage pharmaceutical company advancing first-in-class oral medicines for cancer and other serious conditions, announced today that it will be presenting at the 37th Annual J.P. Morgan Healthcare Conference.

Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today reported that its 500+ gene pan-cancer tumor profiling tissue assay is being used in Merck’s Phase 2 precision oncology KeyImPaCT study of biomarker-directed, pembrolizumab-based combination therapy for advanced non-small-cell lung cancer

Bruin Biometrics, LLC (“BBI”) has been granted U.S. Food and Drug Administration (FDA) marketing authorization for the SEM Scanner,

Pliant Therapeutics, Inc., a biotechnology company focused on discovering, developing and commercializing treatments for fibrotic diseases, today announced that it has dosed the first cohort of subjects in a Phase 1 clinical study evaluating the safety, tolerability, pharmacodynamics and pharmacokinetics of anti-fibrotic agent PLN-74809.